224 related articles for article (PubMed ID: 23460379)
1. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes.
Wright JD; Neugut AI; Ananth CV; Lewin SN; Wilde ET; Lu YS; Herzog TJ; Hershman DL
JAMA Intern Med; 2013 Apr; 173(7):559-68. PubMed ID: 23460379
[TBL] [Abstract][Full Text] [Related]
2. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.
Bokemeyer C; Gascón P; Aapro M; Ludwig H; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; Abraham I; MacDonald K
Support Care Cancer; 2017 Jun; 25(6):1819-1828. PubMed ID: 28111718
[TBL] [Abstract][Full Text] [Related]
3. Management of fever and neutropenia in children with cancer: A survey of Australian and New Zealand practice.
Haeusler GM; Slavin MA; Bryant PA; Babl FE; Mechinaud F; Thursky KA
J Paediatr Child Health; 2018 Jul; 54(7):761-769. PubMed ID: 29655245
[TBL] [Abstract][Full Text] [Related]
4. Adherence to practice guidelines for the management of febrile neutropenia in patients undergoing hematopoietic stem cell transplantation: An observational study in a referral center in Iran.
Ekhtiari Kolour SR; Shahrami B; Kargar M; Taghvaye Masoumi H; Amini S; Vaezi M; Hadjibabaie M; Mohammadi M; Sadeghi K
J Oncol Pharm Pract; 2023 Jul; 29(5):1112-1118. PubMed ID: 35392730
[TBL] [Abstract][Full Text] [Related]
5. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
6. Emergency Department Management of Patients With Febrile Neutropenia: Guideline Concordant or Overly Aggressive?
Baugh CW; Wang TJ; Caterino JM; Baker ON; Brooks GA; Reust AC; Pallin DJ
Acad Emerg Med; 2017 Jan; 24(1):83-91. PubMed ID: 27611638
[TBL] [Abstract][Full Text] [Related]
7. Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study.
Fiegl M; Steger GG; Studnicka M; Eisterer W; Jaeger C; Willenbacher W
Curr Med Res Opin; 2013 May; 29(5):505-15. PubMed ID: 23444969
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
9. Guideline adherence for the management of emergency department patients with febrile neutropenia and no infection source: Is there room for improvement?
Jansma B; Vakkalanka P; Talan DA; Negaard B; Faine BA
J Oncol Pharm Pract; 2020 Sep; 26(6):1382-1389. PubMed ID: 31955667
[TBL] [Abstract][Full Text] [Related]
10. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
11. Outcome of febrile neutropenic patients on granulocyte colony stimulating factor in a tertiary care hospital.
Osmani AH; Ansari TZ; Masood N; Ahmed B
Asian Pac J Cancer Prev; 2012; 13(6):2523-6. PubMed ID: 22938399
[TBL] [Abstract][Full Text] [Related]
12. Emergency department management of chemotherapy related febrile neutropenia: An opportunity to improve care.
Pettit N; Boadu D; Bischof JJ
Am J Emerg Med; 2021 Dec; 50():5-9. PubMed ID: 34265732
[TBL] [Abstract][Full Text] [Related]
13. [Strategies of treatment for febrile neutropenia].
Terui Y
Gan To Kagaku Ryoho; 2013 Jun; 40(6):688-92. PubMed ID: 23863644
[TBL] [Abstract][Full Text] [Related]
14. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
[TBL] [Abstract][Full Text] [Related]
16. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
17. Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia.
Nirenberg A; Reame NK; Cato KD; Larson EL
Oncol Nurs Forum; 2010 Nov; 37(6):765-73. PubMed ID: 21059588
[TBL] [Abstract][Full Text] [Related]
18. Prospective audit of post-chemotherapy febrile neutropenia in patients with solid cancer and lymphoma in two Singaporean cancer centres.
Wong M; Jin J; Tan MH; Lee YM; Lee TE; Ding Y; Yong HC; Lim SE; Chai LY; Chau NM; Hsu LY
Ann Acad Med Singap; 2012 Jul; 41(7):287-93. PubMed ID: 22892605
[TBL] [Abstract][Full Text] [Related]
19. Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.
Poon DMC; Chan K; Chan TW; Ng B; Siu S; Ng J; Johnson D; Lee KC;
Asia Pac J Clin Oncol; 2021 Apr; 17 Suppl 3():39-47. PubMed ID: 33860642
[TBL] [Abstract][Full Text] [Related]
20. Usefulness analysis of the 2018 ASCO/IDSA guideline for outpatient management of fever and neutropenia in adults treated for malignancy.
Hwang S; Kwon KT; Kim Y; Bae S; Chang HH; Kim SW; Yoo SS; Nam SY; Baek JH
Sci Rep; 2021 Sep; 11(1):9048. PubMed ID: 34526516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
